Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

MYMD - MyMD Pharmaceuticals, Inc. Stock Price, Fair Value and News

$1.33+0.02 (+1.53%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MYMD Price Action

MYMD Stock Price

MYMD RSI Chart

2024FebMarAprMayJunJulAugSep0102030405060708090

MYMD Valuation

Market Cap

36.7M

Price/Earnings (Trailing)

-4.65

Price/Sales (Trailing)

23.29

EV/EBITDA

-5.33

Price/Free Cashflow

-4.01

MYMD Price/Sales (Trailing)

2022202320242025050100150200

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MYMD Fundamentals

MYMD Revenue

Revenue (TTM)

1.6M

20142016201820202022202401M2M3M4M5M

MYMD Earnings

Earnings (TTM)

-6.9M

Earnings Growth (Yr)

81.22%

Earnings Growth (Qtr)

-59.7%

201420162018202020222024-35M-30M-25M-20M-15M-10M-5M0

MYMD Profitability

EBT Margin

-438.46%

Return on Equity

-131.03%

Return on Assets

-40.32%

Free Cashflow Yield

-24.97%

MYMD Investor Care

Shares Dilution (1Y)

7350.81%

Diluted EPS (TTM)

-2.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20142015201620172018201901M2M3M4M5M
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20230000
20220000
20210000
20200000
20192.0M1.9M1.8M1.6M
20183.0M2.4M2.3M1.7M
20173.1M3.2M3.3M3.4M
20161.2M2.1M03.0M
20154.4M3.0M1.7M305.6K
20142.8M2.5M2.7M4.7M
20130003.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
 WEBSITEmymd.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

MyMD Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for MyMD Pharmaceuticals, Inc.? What does MYMD stand for in stocks?

MYMD is the stock ticker symbol of MyMD Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MyMD Pharmaceuticals, Inc. (MYMD)?

As of Sun Aug 31 2025, market cap of MyMD Pharmaceuticals, Inc. is 36.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers.

Is MyMD Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether MYMD is over valued or under valued. Whether MyMD Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact MyMD Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYMD.

What is MyMD Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Sun Aug 31 2025, MYMD's PE ratio (Price to Earnings) is -4.65 and Price to Sales (PS) ratio is 23.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYMD PE ratio will change depending on the future growth rate expectations of investors.